Posts by Nir Hacohen, PhD
-
Considering Both Tumor and Immune Features May Improve Prediction of Melanoma Outcomes After Checkpoint Inhibition
Nir Hacohen, PhD, of the Center for Cancer Immunology at the Mass General Cancer Center, and colleagues found that in patients with metastatic melanoma, pre-treatment analysis of both tumor and immune signaling improved the ability to predict response to checkpoint inhibitor immunotherapy and overall survival.
-
Immune Cell Hubs Interact with Malignant Cells in Human Colorectal Cancer
Nir Hacohen, PhD, of the Massachusetts General Hospital Cancer Center, and colleagues developed a novel systematic approach to mapping the immune microenvironment of colorectal cancer and found multicellular interaction networks that may influence response to immunotherapy.
-
Mass General Researchers Find Link Between Protein Signature and Severe Health Decline in COVID-19 Patients
Massachusetts General Hospital researchers led by Marcia Goldberg, MD, and Michael Filbin, MD, discovered the link between an interleukin-6 protein signature and severe health declines in COVID-19 patients.
-
MGH Research Scholars Respond to COVID-19
This video highlights how the MGH Research Scholars rapidly mobilized to address key medical and scientific challenges posed by COVID-19.
-
Biomarkers of T Cell Exhaustion in Checkpoint Inhibitor Therapy
Could altering the balance between two CD8+ T cell states enhance immunotherapies? Research from the Massachusetts General Hospital Cancer Center seeks to find the answer.
Biography
Nir Hacohen is an immunologist and geneticist focused on developing and applying unbiased methods to understand the mammalian immune response. His group is focused on several inter-related areas, including: (i) viral and bacterial sensing in dendritic cells, the sentinel cells of the immune system; (ii) detection of self vs. non-self by the innate immune system; (iii) genetic basis for the observed variation in immunity across the human population, with an emphasis on tumor immunity and autoimmunity; and (iv) novel and personalized immunotherapeutics. He is co-director of the Broad Cell Circuits Program, co-director of the Broad Center for Cell Circuits, and a founding PI of the Broad Genetic Perturbation Platform and Functional Genomics Consortium. Hacohen received an AB in physics from Harvard University and a PhD in biochemistry from Stanford University. After starting his own group as a Whitehead Institute Fellow, he moved to the Broad Institute and joined the faculties of Harvard Medical School and Massachusetts General Hospital.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
